benanomicin-b and Mycoses

benanomicin-b has been researched along with Mycoses* in 2 studies

Other Studies

2 other study(ies) available for benanomicin-b and Mycoses

Article	Year
Water-soluble pradimicin derivatives, synthesis and antifungal evaluation of N,N-dimethyl pradimicins. The Journal of antibiotics, 1990, Volume: 43, Issue:10 Three N,N-dimethyl pradimicins were synthesized by reductive alkylation of pradimicins A, E and FA-2 and evaluated for antifungal activity, water solubility and acute toxicity in mice. They showed in vitro antifungal activity superior to pradimicin A. N,N-Dimethylpradimicins E and FA-2 showed great improvement in water solubility and animal tolerance. N,N-Dimethylpradimicin FA-2 was effective in 3 experimental in vivo fungal infection models. Topics: Alkylation; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antifungal Agents; Candida; Disease Models, Animal; Drug Tolerance; Fungi; Male; Mice; Mice, Inbred ICR; Molecular Structure; Mycoses; Oxidation-Reduction; Solubility	1990
Pradimicins A, B and C: new antifungal antibiotics. II. In vitro and in vivo biological activities. The Journal of antibiotics, 1990, Volume: 43, Issue:7 Pradimicins A, B and C specify novel antibiotics produced by Actinomadura hibisca No. P157-2 (ATCC 53557) possessing potent and broad antifungal activity in vivo. They showed moderate in vitro antifungal activity against a wide variety of fungi and yeasts including clinically important pathogens, and were highly effective in systemic infection with Candida albicans in mice after iv and im administrations. Pradimicin A showed in vivo therapeutic activity against C. albicans, Cryptococcus neoformans and Aspergillus fumigatus in both normal and immunocompromized mice. 5-Fluorocytosine- and azole-resistant C. albicans strains were susceptible to pradimicin A. This antibiotic also demonstrated therapeutic efficacy against lung candidiasis and aspergillosis, vaginal candidiasis and skin Trichophyton mentagrophytes infection in mice with iv or topical treatment. The LD50 values after a single iv or im administration were 120 mg/kg and more than 400 mg/kg, respectively. Against various cultured mammalian cells, pradimicin A was noncytotoxic at 100 or 500 micrograms/ml, and showed potent anti-influenza virus activity with an IC50 value of 6.8 micrograms/ml. Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antifungal Agents; Antiviral Agents; Cells, Cultured; Dermatomycoses; Female; Fungi; Lung Diseases, Fungal; Male; Mice; Mice, Inbred ICR; Mycoses; Orthomyxoviridae; Simplexvirus; Vaginitis; Viral Plaque Assay	1990

Article

Year

Water-soluble pradimicin derivatives, synthesis and antifungal evaluation of N,N-dimethyl pradimicins.

The Journal of antibiotics, 1990, Volume: 43, Issue:10

Three N,N-dimethyl pradimicins were synthesized by reductive alkylation of pradimicins A, E and FA-2 and evaluated for antifungal activity, water solubility and acute toxicity in mice. They showed in vitro antifungal activity superior to pradimicin A. N,N-Dimethylpradimicins E and FA-2 showed great improvement in water solubility and animal tolerance. N,N-Dimethylpradimicin FA-2 was effective in 3 experimental in vivo fungal infection models.

Topics: Alkylation; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antifungal Agents; Candida; Disease Models, Animal; Drug Tolerance; Fungi; Male; Mice; Mice, Inbred ICR; Molecular Structure; Mycoses; Oxidation-Reduction; Solubility

1990

Pradimicins A, B and C: new antifungal antibiotics. II. In vitro and in vivo biological activities.

The Journal of antibiotics, 1990, Volume: 43, Issue:7

Pradimicins A, B and C specify novel antibiotics produced by Actinomadura hibisca No. P157-2 (ATCC 53557) possessing potent and broad antifungal activity in vivo. They showed moderate in vitro antifungal activity against a wide variety of fungi and yeasts including clinically important pathogens, and were highly effective in systemic infection with Candida albicans in mice after iv and im administrations. Pradimicin A showed in vivo therapeutic activity against C. albicans, Cryptococcus neoformans and Aspergillus fumigatus in both normal and immunocompromized mice. 5-Fluorocytosine- and azole-resistant C. albicans strains were susceptible to pradimicin A. This antibiotic also demonstrated therapeutic efficacy against lung candidiasis and aspergillosis, vaginal candidiasis and skin Trichophyton mentagrophytes infection in mice with iv or topical treatment. The LD50 values after a single iv or im administration were 120 mg/kg and more than 400 mg/kg, respectively. Against various cultured mammalian cells, pradimicin A was noncytotoxic at 100 or 500 micrograms/ml, and showed potent anti-influenza virus activity with an IC50 value of 6.8 micrograms/ml.

Topics: Animals; Anthracyclines; Antibiotics, Antineoplastic; Antifungal Agents; Antiviral Agents; Cells, Cultured; Dermatomycoses; Female; Fungi; Lung Diseases, Fungal; Male; Mice; Mice, Inbred ICR; Mycoses; Orthomyxoviridae; Simplexvirus; Vaginitis; Viral Plaque Assay

1990